Navigation Links
EndoChoice(R) Receives 510K Clearance for its BONASTENT(R) Esophageal and Biliary Stent Platforms
Date:4/29/2010

ALPHARETTA, Ga., April 29 /PRNewswire/ -- EndoChoice, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its BONASTENT® Fully Covered Esophageal Stent for the treatment of malignant esophageal obstructions, and its BONASTENT Uncovered Biliary Stent for the treatment of malignant biliary obstructions.

With over 8,000 placements worldwide, the BONASTENT platform has provided physicians treating malignant strictures in the GI tract increased clinical performance attributed to its revolutionary "Hook & Cross" wire geometry. The BONASTENT's proprietary Hook & Cross wire geometry provides segmental compression, reducing stent migration typically experienced with other metal stent platforms.  

"I have been very pleased with my placements of the BONASTENT," said Peter Stevens, M.D., Director of Endoscopy at New York Presbyterian Hospital/Columbia University Medical Center in New York. "It has performed beautifully and I look forward to incorporating future EndoChoice BONASTENT platforms into my practice."

"This revolutionary line of metal stents will make a tremendous impact improving the quality of life for the tens of thousands of patients suffering from GI cancers," said Mark Gilreath, Founder and CEO of EndoChoice.  "We are pleased to have such a successful product launch in the United States and Europe.  Patients can now benefit from the unique feature of segmental compression, only offered in the BONASTENT platform technology."

The BONASTENT platform will be available for hands-on demonstration at the 2010 Digestive Disease Week conference, which is being held in New Orleans on May 2nd through 5th.

BONASTENT Esophageal

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100429/NY95943 )

About EndoChoice, Inc.

EndoChoice designs, manufactures and markets innovative solutions for professionals in gastrointestinal endoscopy worldwide.  Its diverse portfolio of high-quality equipment, devices, supplies and services uniquely positions EndoChoice as a leading resource for GI professionals.  The company strives to exceed its customers' expectations through its superior products, exemplary customer care, knowledgeable sales force, and easy online ordering.  For more information, visit www.EndoChoice.com.


'/>"/>
SOURCE EndoChoice, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EndoChoice(R) Launches CEU Program on Proper Endoscope Reprocessing and a Line of Flexible Endoscope Reprocessing Products
2. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
3. Mylan Receives Approval for Generic Version of Flomax(R)
4. BioMedix Receives Clinical Approval for TRAKnet Software
5. Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
6. Flexuspine Receives FDA Conditional Approval to Begin a Feasibility Study of Its FSU (Functional Spinal Unit) Total Spine Arthroplasty System in the United States
7. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
8. ATS Medical Receives Approval to Commercialize the ATS Simulus Annuloplasty Products in Canada
9. Actavis Receives Approval of Alprazolam ODT in the U.S.
10. Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines
11. Watson Receives FDA Approval for Generic Cardizem(R) LA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Calif. , March 1, 2017   Sun Chlorella ... about all things chlorella, is pleased to announce Non-GMO Project ... premium chlorella powder. Just in time for the ... in Anaheim, CA , Sun Chlorella Corp. ... all chlorella products, including: Sun Chlorella ...
(Date:3/1/2017)... 2017  Integrated Modular Design (IMD), a ... implementation of pre-fabricated healthcare products like bathroom ... seeks to lead the construction industry toward ... Fueled by their leading-edge pre-fabrication solutions, ... construction timelines and project risk, and increasing ...
(Date:3/1/2017)... 1, 2017  Global biotherapeutics leader CSL Behring ... ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as ... reatment with H izentra ® ).  The Phase ... safety and tolerability of two different doses of CSL ... Subcutaneous [Human]), compared with placebo, in the maintenance treatment ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... ... permanently embedded anti-odor solution to cotton knit and woven fabrics. , Retail ... maintaining the luxurious look and feel of cotton. Cotton Incorporated has developed ...
(Date:3/1/2017)... HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... cryoablation for the treatment of early stage breast cancer and where it fits in ... Genes & The Choices We Make .” The event brings together leading cancer and ...
(Date:3/1/2017)... ... March 01, 2017 , ... Expert on international living and leading a ... & Go. , Time & Go app is the ultimate strategic compass that helps ... time management methods enable people to work smarter, not harder, that's why Time & ...
(Date:3/1/2017)... York, NY & Greenwich, CT (PRWEB) , ... March 01, 2017 ... ... many runners, especially in the winter months when people don’t want to stop training ... the knees – and setting the treadmill to a small incline can help protect ...
(Date:3/1/2017)... ... March 01, 2017 , ... “McFarnia”: a suspenseful tale of ... truth about his life and mysterious disappearance. “McFarnia” is the creation of published author ... North Carolina. He currently serves as a Chaplain with Transport for Christ at a ...
Breaking Medicine News(10 mins):